The University of Texas at Austin has launched a new venture studio designed to accelerate the commercialization of university research by building startups focused on real-world challenges, beginning with medical digital twin technologies. The initiative, led by Discovery to Impact at UT Austin, aims to systematically transform academic breakthroughs into market-ready companies capable of delivering clinical and societal impact.
The venture studio will identify market needs and assemble entrepreneurs and university researchers to develop technologies that address those needs. Promising solutions will undergo validation and testing before being spun out as startups with defined value propositions, early customers, and scalable business models. By building ventures around validated market opportunities, the studio seeks to reduce risk and shorten the time required to bring innovations to market.
The initial focus of the venture studio will be health care, specifically the development of medical digital twins. These digital twins are dynamic, data-driven virtual replicas of a patient’s organs or body systems that allow physicians to simulate treatments, run noninvasive tests, and predict how a patient may respond to therapies before administering them. The approach is intended to move medicine beyond generalized treatments and toward more personalized care tailored to individual patients.
The first venture from the studio will be guided by Charles “Charley” Taylor, a professor of internal medicine at Dell Medical School and the W.A. “Tex” Moncrief Jr. chair in computational medicine at the Oden Institute for Computational Engineering and Sciences. Taylor is a recognized leader in artificial intelligence, machine learning, and digital twin technology and is also a co-founder of AI health care company HeartFlow.
University leaders say translating medical breakthroughs into widely adopted clinical services is often slow and expensive due to regulatory approvals, reimbursement hurdles, and operational challenges. UT’s venture studio model is designed to address these barriers by providing shared infrastructure and centralized support services, including compliance, legal, and human resources. This structure allows multiple startups to develop on a common software and operational platform, reducing costs and enabling faster company formation.
The initiative will also draw on UT Austin’s strengths in artificial intelligence, computational medicine, semiconductors, materials science, and robotics. In addition to research expertise, the venture studio will leverage clinical resources associated with UT’s emerging medical center, entrepreneurship programs, and funding from the university’s $10 million UT Seed Fund.
Discovery to Impact, the university organization behind the venture studio, focuses on helping researchers protect intellectual property, license technologies, form partnerships with industry, and launch new companies. Through these efforts, UT aims to translate academic discoveries into products, services, and businesses that contribute to economic growth and societal benefit.
KEY QUOTES:
“We’re creating a new systematic process for launching startups out of UT’s research enterprise that brings the right infrastructure, resources and expertise together to enable faster innovation and product development. It starts by focusing on a real-world need and then creates ventures with a supportive ecosystem around them that solves for that need with products and solutions that benefit our local, state and national economies and society at large. As a public university, it is important that we build public trust by maximizing the return on academic research investments. The venture studio model rigorously validates technology and market fit to ensure that public investments in research are efficiently translated into real-world solutions. Through startup creation, commercial collaborations, and other pathways to market, Discovery to Impact is accelerating the translation of academic research and breakthrough ideas into products and businesses that can change the world.”
Mark Arnold — Associate Vice President Of Discovery To Impact And Managing Director Of Longhorn Ventures At The University Of Texas At Austin
“The market for computational medicine with the use of AI-enabled digital twin technology has the potential to revolutionize personalized patient care and impact how we treat some of the most prevalent medical diseases of our time, like heart disease, dementia and cancer.”
Charles “Charley” Taylor — Professor Of Internal Medicine At Dell Medical School And W.A. “Tex” Moncrief Jr. Chair In Computational Medicine At The Oden Institute For Computational Engineering And Sciences
